{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T14:02:53Z","timestamp":1787320973767,"version":"build-2736575974"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,14]]},"DOI":"10.7759\/cureus.94567","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:53:58Z","timestamp":1760453638000},"source":"Crossref","is-referenced-by-count":2,"title":["Cardiovascular Sequel in Type-2 Diabetes Mellitus Patients on Various Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systemic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Ved","family":"Prakash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"crossref","DOI":"10.6026\/973206300212459","article-title":"Evaluation of cardio-protective effects of a Novel SGLT2 inhibitor beyond glycemic control in preclinical models","volume":"21","author":"Kumar S","year":"2025","unstructured":"Kumar S, Prakash V, Kattimani R, Gupta S. Evaluation of cardio-protective effects of a Novel SGLT2 inhibitor beyond glycemic control in preclinical models. Bioinformation. 2025, 21:2459-63.","journal-title":"Bioinformation"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.6026\/9732063002001862","article-title":"Clinical study evaluating antihyperglycemic efficacy and safety of terminalia arjuna versus sitagliptin in type-2 diabetes mellitus patients","volume":"20","author":"Prakash V","year":"2024","unstructured":"Prakash V, Goel N, Giri KR, Goel A. Clinical study evaluating antihyperglycemic efficacy and safety of terminalia arjuna versus sitagliptin in type-2 diabetes mellitus patients. Bioinformation. 2024, 20:1862-8. 10.6026\/9732063002001862","journal-title":"Bioinformation"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson TR","year":"2018","unstructured":"Einarson TR, Acs A, Ludwig C, Panton UH. Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017. Cardiovasc Diabetol. 2018, 17:83. 10.1186\/s12933-018-0728-6","journal-title":"Cardiovasc Diabetol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijpca.2019.023","article-title":"Study comparing the hypolipidemic effects of Terminalia arjuna with Rosuvastatin on triglyceride and high density lipoprotein- cholesterol levels","volume":"6","author":"Prakash V","year":"2019","unstructured":"Prakash V. Study comparing the hypolipidemic effects of Terminalia arjuna with Rosuvastatin on triglyceride and high density lipoprotein- cholesterol levels. Int J Pharm Chem Anal. 2019, 6:127-35. 10.18231\/j.ijpca.2019.023","journal-title":"Int J Pharm Chem Anal"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.5001\/omj.2012.68","article-title":"Type 2 diabetes mellitus: a review of current trends","volume":"27","author":"Olokoba AB","year":"2012","unstructured":"Olokoba AB, Obateru OA, Olokoba LB. Type 2 diabetes mellitus: a review of current trends. Oman Med J. 2012, 27:269-73. 10.5001\/omj.2012.68","journal-title":"Oman Med J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-016-0149-z","article-title":"Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study","volume":"16","author":"Sakura H","year":"2016","unstructured":"Sakura H, Hashimoto N, Sasamoto K, et al.. Effect of sitagliptin on blood glucose control in patients with type 2 diabetes mellitus who are treatment naive or poorly responsive to existing antidiabetic drugs: the JAMP study. BMC Endocr Disord. 2016, 16:70. 10.1186\/s12902-016-0149-z","journal-title":"BMC Endocr Disord"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1185\/030079906x162746","article-title":"Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes","volume":"23","author":"Pratley RE","year":"2007","unstructured":"Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin. 2007, 23:919-31. 10.1185\/030079906x162746","journal-title":"Curr Med Res Opin"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1130625","article-title":"DPP-4 inhibitors for treating T2DM - hype or hope? An analysis based on the current literature","volume":"10","author":"Saini K","year":"2023","unstructured":"Saini K, Sharma S, Khan Y. DPP-4 inhibitors for treating T2DM - hype or hope? An analysis based on the current literature. Front Mol Biosci. 2023, 10:1130625. 10.3389\/fmolb.2023.1130625","journal-title":"Front Mol Biosci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.18231\/j.ijpp.2020.006","article-title":"Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride withmetformin on patients of type-2 diabetes mellitus","volume":"7","author":"Prakash V","year":"2020","unstructured":"Prakash V, Goel N, Verma S. Comparative study analyzing efficacy and safety of sitagliptin with metformin versus glimepiride withmetformin on patients of type-2 diabetes mellitus. Indian J Pharm Pharmacol. 2020, 7:26-33. 10.18231\/j.ijpp.2020.006","journal-title":"Indian J Pharm Pharmacol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9040912","article-title":"Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes","volume":"9","author":"Patti AM","year":"2020","unstructured":"Patti AM, Rizvi AA, Giglio RV, Stoian AP, Ligi D, Mannello F. Impact of glucose-lowering medications on cardiovascular and metabolic risk in type 2 diabetes. J Clin Med. 2020, 9:912. 10.3390\/jcm9040912","journal-title":"J Clin Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.2337\/cd16-0005","article-title":"More than 7 years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications","volume":"34","author":"Regier EE","year":"2016","unstructured":"Regier EE, Venkat MV, Close KL. More than 7 years of hindsight: revisiting the FDA's 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications. Clin Diabetes. 2016, 34:173-80. 10.2337\/cd16-0005","journal-title":"Clin Diabetes"},{"key":"ref12","article-title":"Dipeptidyl peptidase IV (DPP IV) inhibitors","author":"Kasina SVSK","year":"2025","unstructured":"Kasina SVSK, Baradhi KM. Dipeptidyl peptidase IV (DPP IV) inhibitors. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2025."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/cl2.1230","article-title":"PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis","volume":"18","author":"Haddaway NR","year":"2022","unstructured":"Haddaway NR, Page MJ, Pritchard CC, McGuinness LA. PRISMA2020: an R package and Shiny app for producing PRISMA 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Syst Rev. 2022, 18:e1230. 10.1002\/cl2.1230","journal-title":"Campbell Syst Rev"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.13105\/wjma.v5.i4.80","article-title":"Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale","volume":"5","author":"Luchini C","year":"2017","unstructured":"Luchini C, Stubbs B, Solmi M, Veronese N. Assessing the quality of studies in meta-analyses: advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal. 2017, 5:80-4. 10.13105\/wjma.v5.i4.80","journal-title":"World J Meta-Anal"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1307684","article-title":"Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus","volume":"369","author":"Scirica BM","year":"2013","unstructured":"Scirica BM, Bhatt DL, Braunwald E, et al.. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013, 369:1317-26. 10.1056\/NEJMoa1307684","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1305889","article-title":"Alogliptin after acute coronary syndrome in patients with type 2 diabetes","volume":"369","author":"White WB","year":"2013","unstructured":"White WB, Cannon CP, Heller SR, et al.. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013, 369:1327-35. 10.1056\/NEJMoa1305889","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1501352","article-title":"Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes","volume":"373","author":"Green JB","year":"2015","unstructured":"Green JB, Bethel MA, Armstrong PW, et al.. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015, 373:232-42. 10.1056\/NEJMoa1501352","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.18269","article-title":"Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial","volume":"321","author":"Rosenstock J","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, et al.. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial. JAMA. 2019, 321:69-79. 10.1001\/jama.2018.18269","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.13772","article-title":"Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. The CAROLINA Randomized Clinical Trial","volume":"322","author":"Rosenstock J","year":"2019","unstructured":"Rosenstock J, Kahn SE, Johansen OE, et al.. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes. The CAROLINA Randomized Clinical Trial. JAMA. 2019, 322:1155-66. 10.1001\/jama.2019.13772","journal-title":"JAMA"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2017.08.004","article-title":"Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial","volume":"6","author":"McMurray JJ","year":"2018","unstructured":"McMurray JJ, Ponikowski P, Bolli GB, et al.. Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial. JACC Heart Fail. 2018, 6:8-17. 10.1016\/j.jchf.2017.08.004","journal-title":"JACC Heart Fail"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.12252","article-title":"Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE)","volume":"67","author":"Mathieu C","year":"2013","unstructured":"Mathieu C, Barnett AH, Brath H, et al.. Effectiveness and tolerability of second-line therapy with vildagliptin vs. other oral agents in type 2 diabetes: a real-life worldwide observational study (EDGE). Int J Clin Pract. 2013, 67:947-56. 10.1111\/ijcp.12252","journal-title":"Int J Clin Pract"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/420768-cardiovascular-sequel-in-type-2-diabetes-mellitus-patients-on-various-dipeptidyl-peptidase-4-dpp-4-inhibitors-a-systemic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T14:54:04Z","timestamp":1760453644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/420768-cardiovascular-sequel-in-type-2-diabetes-mellitus-patients-on-various-dipeptidyl-peptidase-4-dpp-4-inhibitors-a-systemic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":22,"URL":"https:\/\/doi.org\/10.7759\/cureus.94567","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10,14]]}}}